Zerumbone, a phytochemical of subtropical ginger, protects against hyperglycemia-induced retinal damage in experimental diabetic rats

Nutrients

Volumn 8, Issue 8, 2016, Pages

  Tzeng, Thing Fong ^a   Liou, Shorong Shii ^a   Tzeng, Yu Cheng ^b   Liu, I Min ^a  

^a TAJEN UNIVERSITY   (Taiwan)

^b St Dominic s Catholic High School   (Taiwan)

Author keywords

AGEs; Diabetic retinopathy; NF B; Zerumbone

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; GLUCOSE; HEMOGLOBIN A1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; ZERUMBONE; ADVANCED GLYCATION END PRODUCT RECEPTOR; AGER PROTEIN, RAT; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; CYTOKINE; GLYCOSYLATED HEMOGLOBIN; ICAM1 PROTEIN, RAT; NONSTEROID ANTIINFLAMMATORY AGENT; SESQUITERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE PROTECTION; GENE EXPRESSION REGULATION; GINGER; HISTOPATHOLOGY; HYPERGLYCEMIA; MALE; MICROSCOPY; NONHUMAN; PHYTOCHEMISTRY; RAT; REAL TIME POLYMERASE CHAIN REACTION; RETINAL INNER NUCLEAR LAYER; RETINAL INNER PLEXIFORM LAYER; RETINAL NERVE FIBER LAYER THICKNESS; RETINAL OUTER NUCLEAR LAYER; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; WESTERN BLOTTING; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; COMPLICATION; DIET THERAPY; DIETARY SUPPLEMENT; EXPERIMENTAL DIABETES MELLITUS; IMMUNOLOGY; METABOLISM; PATHOLOGY; RANDOMIZATION; RETINA; RHIZOME; WISTAR RAT; ZINGIBERACEAE;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOMARKERS; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DIETARY SUPPLEMENTS; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INTERCELLULAR ADHESION MOLECULE-1; MALE; NF-KAPPA B; RANDOM ALLOCATION; RATS, WISTAR; RETINA; RHIZOME; SESQUITERPENES; VASCULAR ENDOTHELIAL GROWTH FACTORS; ZINGIBERACEAE;

EID: 84980373420     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu8080449     Document Type: Article

References (38)

1. Antonetti, D.A.; Klein, R.; Gardner, T.W. Diabetic retinopathy. N. Engl. J. Med. 2012, 366, 1227-1239. [CrossRef] [PubMed]
2. Rask-Madsen, C.; King, G.L. Vascular complications of diabetes: Mechanisms of injury and protective factors. Cell Metab. 2013, 17, 20-33. [CrossRef] [PubMed]
3. Nentwich, M.M.; Ulbig, M.W. Diabetic retinopathy-ocular complications of diabetes mellitus. World J. Diabetes 2015, 6, 489-499. [CrossRef] [PubMed]
4. Adler, A.I.; Stevens, R.J.; Neil, A.; Stratton, I.M.; Boulton, A.J.; Holman, R.R. UKPDS 59: Hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002, 5, 894-899. [CrossRef]
5. Hsu, C.R.; Chen, Y.T.; Sheu, W.H. Glycemic variability and diabetes retinopathy: A missing link. J. Diabetes Complicat. 2015, 29, 302-306. [CrossRef] [PubMed]
6. Mattila, T.K.; de Boer, A. Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus. Drugs 2010, 70, 2229-2245. [CrossRef] [PubMed]
7. Tang, J.; Kern, T.S. Inflammation in diabetic retinopathy. Prog. Retin. Eye Res. 2011, 30, 343-358. [CrossRef] [PubMed]
8. Semeraro, F.; Cancarini, A.; dell’Omo, R.; Rezzola, S.; Romano, M.R.; Costagliola, C. Diabetic retinopathy: vascular and inflammatory disease. J. Diabetes Res. 2015, 2015, 582060. [CrossRef] [PubMed]
9. Kaštelan, S.; Tomić, M.; Gverović Antunica, A.; Salopek Rabatić, J.; Ljubić, S. Inflammation and pharmacological treatment in diabetic retinopathy. Mediat. Inflamm. 2013, 2013, 213130. [CrossRef] [PubMed]
10. Hammes, H.P.; Alt, A.; Niwa, T.; Clausen, J.T.; Bretzel, R.G.; Brownlee, M.; Schleicher, E.D. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 1999, 42, 728-736. [CrossRef] [PubMed]
11. Yamagishi, S.; Nakamura, K.; Matsui, T. Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy. Curr. Drug Discov. Technol. 2006, 3, 83-88. [CrossRef] [PubMed]
12. Chen, M.; Curtis, T.M.; Stitt, A.W. Advanced glycation end products and diabetic retinopathy. Curr. Med. Chem. 2013, 20, 3234-3240. [CrossRef] [PubMed]
13. Yob, N.J.; Jofrry, S.M.; Affandi, M.M.; Teh, L.K.; Salleh, M.Z.; Zakaria, Z.A. Zingiber zerumbet (L.) Smith: A review of its ethnomedicinal, chemical, and pharmacological uses. Evid. Based Complement. Altern. Med. 2011, 2011, 543216. [CrossRef] [PubMed]
14. Dung, N.X.; Chinh, T.D.; Rang, D.D.; Leclercq, P.A. The constituents of the rhizome oil of Zingiber zerumbet (L.) sm. from Vietnam. J. Essent. Oil Res. 1993, 5, 553-555. [CrossRef]
15. Murakami, A.; Takahashi, D.; Kinoshita, T.; Koshimizu, K.; Kim, H.W.; Yoshihiro, A.; Nakamura, Y.; Jiwajinda, S.; Terao, J.; Ohigashi, H. Zerumbone, a Southeast Asian ginger sesquiterpene, markedly suppresses free radical generation, proinflammatory protein production, and cancer cell proliferation accompanied by apoptosis: The alpha, beta-unsaturated carbonyl group is a prerequisite. Carcinogenesis 2002, 23, 795-802. [CrossRef] [PubMed]
16. Chen, B.Y.; Lin, D.P.; Wu, C.Y.; Teng, M.C.; Sun, C.Y.; Tsai, Y.T.; Su, K.C.; Wang, S.R.; Chang, H.H. Dietary zerumbone prevents mouse cornea from UVB-induced photokeratitis through inhibition of NF-κB, iNOS, and TNF-α expression and reduction of MDA accumulation. Mol. Vis. 2011, 6, 854-863.
17. Tzeng, T.F.; Liou, S.S.; Chang, C.J.; Liu, I.M. Zerumbone, a natural cyclic sesquiterpene of Zingiber zerumbet Smith, attenuates nonalcoholic fatty liver disease in hamsters fed on high-fat diet. Evid. Based Complement. Altern. Med. 2013, 2013, 303061. [CrossRef] [PubMed]
18. Tzeng, T.F.; Liou, S.S.; Chang, C.J.; Liu, I.M. Zerumbone, a tropical ginger sesquiterpene, ameliorates streptozotocin-induced diabetic nephropathy in rats by reducing the hyperglycemia-induced inflammatory response. Nutr. Metab. 2013, 10, 64. [CrossRef] [PubMed]
19. Hong, T.Y.; Tzeng, T.F.; Liou, S.S.; Liu, I.M. The ethanol extract of Zingiber zerumbet rhizomes mitigates vascular lesions in the diabetic retina. Vasc. Pharmacol. 2016, 76, 18-27. [CrossRef] [PubMed]
20. Kern, T.S.; Tang, J.; Berkowitz, B.A. Validation of structural and functional lesions of diabetic retinopathy in mice. Mol. Vis. 2010, 16, 2121-2131. [PubMed]
21. Lai, A.K.W.; Lo, A.C.Y. Animal models of diabetic retinopathy: Summary and comparison. J. Diabetes Res. 2013, 2013, 106594. [CrossRef] [PubMed]
22. Abdel Wahab, S.I.; Abdul, A.B.; Alzubairi, A.S.; Mohamed Elhassan, M.; Mohan, S. In vitro ultramorphological assessment of apoptosis induced by zerumbone on (HeLa). J. Biomed. Biotechnol. 2009, 2009, 769568. [CrossRef] [PubMed]
23. Kim, J.; Kim, C.S.; Sohn, E.; Lee, Y.M.; Jo, K.; Shin, S.D.; Kim, J.S. Aminoguanidine protects against apoptosis of retinal ganglion cells in Zucker diabetic fatty rats. Eur. Rev. Med. Pharmacol. Sci. 2014, 18, 1573-1578. [PubMed]
24. +/calmodulin-dependent protein kinase II activity in diabetic mouse retina. Diabetes 2010, 59, 1825-1835. [CrossRef] [PubMed]
25. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-DDCT method. Methods 2001, 25, 402-408. [CrossRef] [PubMed]
26. Kern, T.S.; Engerman, R.L. Pharmacological inhibition of diabetic retinopathy: Aminoguanidine and aspirin. Diabetes 2001, 50, 1636-1642. [CrossRef] [PubMed]
27. Kojić Damjanov, S.; Ðerić, M.; Eremić Kojić, N. Glycated hemoglobin A1c as a modern biochemical marker of glucose regulation. Med. Pregl. 2014, 67, 339-344. [CrossRef] [PubMed]
28. Vlassara, H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab. Res. Rev. 2001, 17, 436-443. [CrossRef] [PubMed]
29. Stitt, A.W.; He, C.; Vlassara, H. Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. Biochem. Biophys. Res. Commun. 1999, 256, 549-556. [CrossRef] [PubMed]
30. Lecleire-Collet, A.; Tessier, L.H.; Massin, P.; Forster, V.; Brasseur, G.; Sahel, J.A.; Picaud, S. Advanced glycation end products can induce glial reaction and neuronal degeneration in retinal explants. Br. J. Ophthalmol. 2005, 89, 1631-1633. [CrossRef] [PubMed]
31. Fogli, S.; Mogavero, S.; Egan, C.G.; Del Re, M.; Danesi, R. Pathophysiology and pharmacological targets of VEGF in diabetic macular edema. Pharmacol. Res. 2016, 103, 149-157. [CrossRef] [PubMed]
32. Kowluru, R.A.; Koppolu, P.; Chakrabarti, S.; Chen, S. Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. Free Radic. Res. 2003, 37, 1169-1180. [CrossRef] [PubMed]
33. Kim, J.; Kim, K.M.; Kim, C.S.; Sohn, E.; Lee, Y.M.; Jo, K.; Kim, J.S. Puerarin inhibits the retinal pericyte apoptosis induced by advanced glycation end products in vitro and in vivo by inhibiting NADPH oxidase-related oxidative stress. Free Radic. Biol. Med. 2012, 53, 357-365. [CrossRef] [PubMed]
34. Zheng, L.; Szabo, C.; Kern, T.S. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 2004, 53, 2960-2967. [CrossRef] [PubMed]
35. Romeo, G.; Liu, W.H.; Asnaghi, V.; Kern, T.S.; Lorenzi, M. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a Proapoptotic Program in retinal pericytes. Diabetes 2002, 51, 2241-2248. [CrossRef] [PubMed]
36. Safi, S.Z.; Qvist, R.; Kumar, S.; Batumalaie, K.; Ismail, I.S. Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets. Biomed. Res. Int. 2014, 2014, 801269. [CrossRef] [PubMed]
37. Cuzzolin, L.; Zaffani, S.; Benoni, G. Safety implications regarding use of phytomedicines. Eur. J. Clin. Pharmacol. 2006, 62, 37-42. [CrossRef] [PubMed]
38. Ibrahim, M.Y.; Abdul, A.B.; Ibrahim, T.A.T.; Abdelwahab, S.I.; Elhassan, M.M.; Syam, M.M. Evaluation of acute toxicity and the effect of single injected doses of zerumbone on the kidney and liver functions in Sprague Dawley rats. Afr. J. Biotechnol. 2010, 9, 4442-4450.